Saturday, July 11, 2026

Patent directory · USPTO A61K / A61P

Patents matching “inhibitor”

2,878 pharma patents match "inhibitor" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 2,878
Index total 30,257
Page 6 / 120

Quick answer

This filtered view shows 2,878 pharmaceutical patents matching "inhibitor" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

2,878 results for “inhibitor” · 30,257 patents in full index Clear search

  1. US 12234460

    Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  2. US 12233051

    Treating primary or idiopathic hyperoxaluria with small molecule inhibitors of lactate dehydrogenase

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 25, 2025 · Expires Feb 20, 2045

    granted
  3. US 12227508

    TGF-β inhibitors

    Rigel Pharmaceuticals, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  4. US 12226425

    Inhibitors of ARG1 and/or ARG2

    Arcus Biosciences, Inc. · Granted Feb 18, 2025 · Expires Feb 13, 2045

    granted
  5. US 12221491

    PSMD9 inhibitors for the treatment of hepatic lipid dysregulation

    The Regents of the University of California · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  6. US 12220415

    WEE1 kinase inhibitors and methods of treating cancer using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  7. US 12220421

    Inhibitors of C. difficile spore germination

    THE BOARDS OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  8. US 12221441

    Plasma kallikrein inhibitors and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Feb 11, 2025 · Expires Feb 6, 2045

    granted
  9. US 12219327

    Substituted isoindolines as PI3K-alpha inhibitors

    Relay Therapeutics, Inc. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  10. US 12215322

    Treatment of liver disease with mitochondrial glycerol-3-phosphate acyltransferase (GPAM) inhibitors

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  11. US 12213973

    Bacterial nitric oxide synthase inhibitors

    Northwestern University · Granted Feb 4, 2025 · Expires Jan 30, 2045

    granted
  12. US 12209085

    RET inhibitors, pharmaceutical compositions and uses thereof

    SUNSHINE LAKE PHARMA CO., LTD. · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted
  13. US 12209116

    Recombinant human C1 esterase inhibitor and uses thereof

    Takeda Pharmaceutical Company Limited · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted
  14. US 12209073

    Polymorphs of a dihydroorotate dehydrogenase (DHOD) inhibitor

    KIORA PHARMACEUTICALS GmbH · Granted Jan 28, 2025 · Expires Jan 23, 2045

    granted
  15. US 12202845

    Ras inhibitors

    Revolution Medicines, Inc. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  16. US 12201617

    HDAC6 inhibitors for treatment of metabolic disease and HFpEF

    Tenaya Therapeutics, Inc. · Granted Jan 21, 2025 · Expires Jan 16, 2045

    granted
  17. US 12186313

    Pyridazinone compounds and their use as DAAO inhibitors

    Takeda Pharmaceutical Company Limited · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  18. US 12187746

    C26-linked rapamycin analogs as mTOR inhibitors

    Revolution Medicines, Inc. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  19. US 12187754

    LpxC inhibitors and uses thereof

    BLACKSMITH MEDICINES, INC. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  20. US 12186324

    Imidazopiperazine inhibitors of transcription activating proteins

    The Board of Regents of the University of Texas System · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  21. US 12187792

    IL-4/IL-13 pathway inhibitors for enhanced efficacy in treating cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  22. US 12187694

    SLC26A3 inhibitors and use thereof

    The Regents of the University of California · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  23. US 12187731

    Compounds useful as inhibitors of ATR kinase

    Vertex Pharmaceuticals Incorporated · Granted Jan 7, 2025 · Expires Jan 2, 2045

    granted
  24. US 12172994

    Pyrimidine compound as JAK kinase inhibitor

    Theravance Biopharma R&D IP, LLC · Granted Dec 24, 2024 · Expires Dec 19, 2044

    granted